|
Published by: Medtech Insight
Published: Jan. 1, 2008 - 129 Pages
Table of Contents
- EXECUTIVE SUMMARY
- i. Osteoporosis Incidence and Prevalence
- ii. Osteoporosis Diagnosis and Management
- a. Bone Densitometry
- b. Biochemical Markers
- c. Osteoporosis Treatments
- iii. Market Analysis
- a. Bone Densitometry Systems
- b. Biochemical Markers
- c. Hormone Replacement Therapy and Osteoporosis Drugs
- i. Hormone Replacement Therapy Drugs
- ii. Osteoporosis Drugs
- iv. Methodology
- Exhibit ES-1: 2007, Osteoporosis-Caused Fracture Incidence, by Site
- Exhibit ES-2: Osteoporosis Management Products, Combined Market Forecast, 2005-2010
- Exhibit ES-3: Total Bone Densitometry Systems, Market Forecast, 2005-2010
- Exhibit ES-4: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2005-2010
- Exhibit ES-5: 2007, Hormone Replacement Therapy and Osteoporosis Drugs, Sales by Product Category
- Exhibit ES-6: Hormone Replacement Therapy Drugs, Market Forecast, 2005-2010
- Exhibit ES-7: Osteoporosis Drugs, Market Forecast, 2005-2010
- Exhibit ES-8: Hormone Replacement Therapy and Osteoporosis Drugs, Market Forecast, 2005-2010
- 1. OSTEOPOROSIS MANAGEMENT PRODUCTS MARKET
- 1.1 Overview of Osteoporosis
- 1.1.1 Incidence, Prevalence, and Cost
- 1.1.2 Types of Osteoporosis
- 1.1.3 Risk Factors
- 1.2 Diagnosis
- 1.2.1 Bone Densitometry
- 1.2.1.1 Products, by Application
- 1.2.1.1.1 Hospital-Based Densitometry Systems
- 1.2.1.1.2 Office-Based Densitometry Systems
- 1.2.1.1.3 Software-Based Systems
- 1.2.1.2 Products and Suppliers
- 1.2.1.2.1 CooperSurgical/The Cooper Companies
- 1.2.1.2.2 GE Healthcare/General Electric Company
- 1.2.1.2.3 Hologic
- 1.2.1.3 Market Analysis
- 1.2.1.4 Competitive Analysis
- 1.2.2 Biochemical Markers
- 1.2.2.1 Types
- 1.2.2.2 Applications
- 1.2.2.3 Products and Suppliers
- 1.2.2.3.1 Beckman Coulter
- 1.2.2.3.2 Roche Diagnostics/F. Hoffmann- La Roche/Roche Holding
- 1.2.2.3.3 Inverness Medical Innovations
- 1.2.2.3.4 Orion Diagnostica Oy/Orion Group
- 1.2.2.3.5 Quidel
- 1.2.2.4 Market Analysis
- 1.2.2.5 Competitive Analysis
- 1.3 Treatment
- 1.3.1 Antiresorptive Drugs
- 1.3.1.1 Estrogen
- 1.3.1.2 Selective Estrogen Receptor Modulators
- 1.3.1.2.1 EVISTA
- 1.3.1.3 Calcitonins
- 1.3.1.4 Bisphosphonates
- 1.3.1.4.1 Actonel
- 1.3.1.4.2 Boniva
- 1.3.1.4.3 FOSAMAX
- 1.3.2 Bone-Forming Drugs
- 1.3.2.1 Sodium Fluoride
- 1.3.2.2 Parathyroid Hormone
- 1.3.2.2.1 FORTÉO
- 1.3.3 Dual-Acting Drug
- 1.3.4 Other Treatments
- 1.3.4.1 Monoclonal Antibodies
- 1.3.4.2 Cathepsin K Inhibitors
- 1.3.4.3 Gene Therapy
- 1.3.4.4 Statin Drugs
- 1.3.4.5 Selective Androgen Receptor Modulators
- 1.3.5 Market Analysis
- 1.3.5.1 Hormone Replacement Therapy Drugs
- 1.3.5.2 Osteoporosis Drugs
- 1.3.6 Competitive Analysis
- 1.3.7 Combined Market Analysis
- Exhibit 1-1: 2007, Osteoporosis-Caused Fracture Incidence, by Site
- Exhibit 1-2: Prevalence of Osteoporosis and Low Bone Mass in Men and Women Age 50 and Older, by Ethnicity
- Exhibit 1-3: Types of Osteoporosis
- Exhibit 1-4: Leading Risk Factors for Osteoporosis
- Exhibit 1-5: Comparison of Bone Densitometry and Osteoporosis Biochemical Marker Screenings
- Exhibit 1-6: Imaging Technologies Used to Diagnose Osteoporosis
- Exhibit 1-7: 2008, Selected Bone Densitometry Systems
- Exhibit 1-8: Bone Densitometry Hospital Systems, Market Forecast, 2005-2010
- Exhibit 1-9: Bone Densitometry Office Systems, Market Forecast, 2005-2010
- Exhibit 1-10: Total Bone Densitometry Systems, Market Forecast, 2005-2010
- Exhibit 1-11: 2007, Bone Densitometry Systems Market, Share by Supplier
- Exhibit 1-12: Comparison of Bone Remodeling Biochemical Markers
- Exhibit 1-13: 2008, Selected Bone Remodeling Biochemical Marker Tests
- Exhibit 1-14: Bone Remodeling Biochemical Marker Tests, Market Forecast, 2005-2010
- Exhibit 1-15: 2007, Bone Remodeling Biochemical Marker Tests Market, Share by Supplier
- Exhibit 1-16: 2008, Selected Current and Emerging Pharmaceutical Treatments for Osteoporosis
- Exhibit 1-17: Hormone Replacement Therapy and Osteoporosis Drugs, Market Forecast, 2005-2010
- Exhibit 1-18: 2007, Hormone Replacement Therapy and Osteoporosis Drugs, Sales by Product Category
- Exhibit 1-19: Hormone Replacement Therapy Drugs, Market Forecast, 2005-2010
- Exhibit 1-20: Osteoporosis Drugs, Market Forecast, 2005-2010
- Exhibit 1-21: 2007, Hormone Replacement Therapy and Osteoporosis Drugs Market, Share by Supplier
- Exhibit 1-22: Osteoporosis Management Products, Combined Market Forecast, 2005-2010
- 2. COMPANY PROFILES
- 2.1 The Cooper Companies, Inc.
- 2.2 General Electric Company
- 2.3 Hologic, Inc.
- 2.4 Inverness Medical Innovations, Inc.
- 2.5 Eli Lilly and Company
- 2.6 Merck & Company, Inc.
- 2.7 Novartis AG
- 2.8 Procter & Gamble Company
- 2.9 Quidel Corporation
- 2.10 Roche Holding AG
- 2.11 Wyeth
- APPENDIX: COMPANY LISTING
AbstractIn 2007, the United States (U.S.) market for osteoporosis management products totaled approximately $7.6 billion. Sales of these products are expected to increase at a compound annual rate of 6.6%, reaching an estimated $9.3 billion in the year 2010.
This new report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. osteoporosis management products market. According to the first-ever U.S. Surgeon General’s report on the nation’s bone health, by the year 2020 one out of two Americans over the age of 50 will be at risk for fractures from osteoporosis. Currently, approximately 10 million people in the U.S. are estimated to have osteoporosis, and another 34 million are believed to have low bone mass, placing them at risk for developing osteoporosis.
Products for the diagnosis and treatment of osteoporosis that are covered in this report include biochemical markers, bone densitometry systems, and hormone replacement and osteoporosis drugs. These include antiresorptive drugs such as bisphosphonates, calcitonins, estrogen, and selective estrogen receptor modulators; bone-forming drugs such as parathyroid hormone and sodium fluoride; combination drugs; and treatments such as cathepsin K inhibitors, gene therapy, monoclonal antibodies, selective androgen receptor modulators, and statin drugs.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
